# CW-301 FIH Study of CAN016

> **NCT07664150** · PHASE1,PHASE2 · RECRUITING · sponsor: **Canwell Biotech Limited** · enrollment: 90 (estimated)

## Conditions studied

- Patients With Advanced Solid Tumors

## Interventions

- **DRUG:** CAN016
- **DRUG:** CAN016

## Key facts

- **NCT ID:** NCT07664150
- **Lead sponsor:** Canwell Biotech Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-18
- **Primary completion:** 2028-12-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07664150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07664150, "CW-301 FIH Study of CAN016". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07664150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*